Company News 

Indivior back on firmer footing as new drug gains backing

Indivior back on firmer footing as new drug gains backing

Indivior’s (INDV) shares have recouped almost all of their recent losses after two US advisory bodies voted to approve the group’s new opioid addiction drug. Eighteen out of 19 members of the two committees voted in favour of RBP-6000, which is now expected to be given the green light by US regulators in November.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now